The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen-sensitive breast cancer: A systematic review and meta-analysis.

IF 2.7 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Reproductive Medicine and Biology Pub Date : 2023-09-23 eCollection Date: 2023-01-01 DOI:10.1002/rmb2.12543

Tsukasa Yoshida, Osamu Takahashi, Yoko Suzuki, Erika Ota, Tetsuya Hirata

{"title":"The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen-sensitive breast cancer: A systematic review and meta-analysis.","authors":"Tsukasa Yoshida, Osamu Takahashi, Yoko Suzuki, Erika Ota, Tetsuya Hirata","doi":"10.1002/rmb2.12543","DOIUrl":null,"url":null,"abstract":"Purpose: Tamoxifen is used for the suppression of estrogen-sensitive tumor recurrence in oocyte retrieval cycles. This meta-analysis aimed to evaluate the quality of controlled ovarian stimulation (COS) with co-administration of gonadotropins and tamoxifen (COS with tamoxifen).Methods: PubMed, Embase, and Cochrane Library were searched for articles on October 30, 2022. The authors included studies comparing COS with tamoxifen and COS with gonadotropins and letrozole (COS with letrozole) or gonadotropin only (COS with gonadotropin only) for fertility preservation in patients with breast cancer. The main outcome measures were the COS quality, total number of retrieved oocytes (TOR), total number of mature oocytes (TMO), and peak estradiol levels (PEL).Results: Four studies (348 patients, two randomized controlled trials, and two cohort studies) were included in our meta-analysis. There was no significant difference in TOR (95% CI, [-3.84, 2.90]) and TMO (95% CI, [-2.20, 2.64]) between COS with tamoxifen and COS with letrozole. There was also no difference in TOR (95% CI, [-6.14, 1.86]) between COS with tamoxifen and COS with gonadotropin only. Statistically significant decrease was observed in PEL during COS with letrozole compared with tamoxifen (95% CI, [1414.4, 4953.7]).Conclusions: The quality did not differ between COS with tamoxifen and COS with letrozole or gonadotropin only.","PeriodicalId":21116,"journal":{"name":"Reproductive Medicine and Biology","volume":"22 1","pages":"e12543"},"PeriodicalIF":2.7000,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517303/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Medicine and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/rmb2.12543","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Tamoxifen is used for the suppression of estrogen-sensitive tumor recurrence in oocyte retrieval cycles. This meta-analysis aimed to evaluate the quality of controlled ovarian stimulation (COS) with co-administration of gonadotropins and tamoxifen (COS with tamoxifen).

Methods: PubMed, Embase, and Cochrane Library were searched for articles on October 30, 2022. The authors included studies comparing COS with tamoxifen and COS with gonadotropins and letrozole (COS with letrozole) or gonadotropin only (COS with gonadotropin only) for fertility preservation in patients with breast cancer. The main outcome measures were the COS quality, total number of retrieved oocytes (TOR), total number of mature oocytes (TMO), and peak estradiol levels (PEL).

Results: Four studies (348 patients, two randomized controlled trials, and two cohort studies) were included in our meta-analysis. There was no significant difference in TOR (95% CI, [-3.84, 2.90]) and TMO (95% CI, [-2.20, 2.64]) between COS with tamoxifen and COS with letrozole. There was also no difference in TOR (95% CI, [-6.14, 1.86]) between COS with tamoxifen and COS with gonadotropin only. Statistically significant decrease was observed in PEL during COS with letrozole compared with tamoxifen (95% CI, [1414.4, 4953.7]).

Conclusions: The quality did not differ between COS with tamoxifen and COS with letrozole or gonadotropin only.

Abstract Image

查看原文本刊更多论文

他莫昔芬控制性卵巢刺激治疗雌激素敏感性乳腺癌症患者的有效性：一项系统综述和荟萃分析。

目的：三苯氧胺用于抑制卵母细胞回收周期中雌激素敏感性肿瘤的复发。本荟萃分析旨在评估促性腺激素和三苯氧胺联合给药的控制性卵巢刺激（COS）的质量。方法：检索PubMed、Embase和Cochrane Library于2022年10月30日发表的文章。作者纳入了比较COS与他莫昔芬和COS与促性腺激素和来曲唑（COS与来曲唑）或仅促性腺激素（COS仅促性腺素）在癌症患者中保持生育能力的研究。主要结果指标是COS质量、回收卵母细胞总数（TOR）、成熟卵母细胞总量（TMO）和雌二醇峰值水平（PEL）。结果：我们的荟萃分析包括四项研究（348名患者、两项随机对照试验和两项队列研究）。三苯氧胺COS和来曲唑COS的TOR（95%CI，[3.84，2.90]）和TMO（95%CI（-2.20，2.64]）无显著差异。含三苯氧胺的COS和仅含促性腺激素的COS在TOR方面也没有差异（95%CI，[6.14,1.86]）。与三苯氧胺相比，来曲唑COS期间的PEL显著降低（95%CI，[1414.44953.7]）。结论：三苯氧芬COS和来曲唑或促性腺激素COS的质量没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reproductive Medicine and Biology Multiple-

CiteScore

5.70

自引率

5.90%

发文量

审稿时长

20 weeks

期刊介绍： Reproductive Medicine and Biology (RMB) is the official English journal of the Japan Society for Reproductive Medicine, the Japan Society of Fertilization and Implantation, the Japan Society of Andrology, and publishes original research articles that report new findings or concepts in all aspects of reproductive phenomena in all kinds of mammals. Papers in any of the following fields will be considered: andrology, endocrinology, oncology, immunology, genetics, function of gonads and genital tracts, erectile dysfunction, gametogenesis, function of accessory sex organs, fertilization, embryogenesis, embryo manipulation, pregnancy, implantation, ontogenesis, infectious disease, contraception, etc.